Sapience Therapeutics
Manufacturing · New York, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
500 Mamaroneck Ave Ste 3200, Harrison, N...Phone Number
(914) 607-6931Website
www.sapiencetherapeutics.comRevenue
$12.4 MillionIndustry
About Sapience Therapeutics
Sapience Therapeutics is focused on revolutionizing oncology through innovative peptide therapeutics that target elusive oncogenic proteins. Their product pipeline includes SPEARs and SPARCs, with two lead candidates, lucicebtide (ST101) and ST316, currently in Phase 2 clinical trials. The company aims to provide precision therapies for patients with various cancers, including glioblastoma and colorectal cancer. Their services include conducting clinical trials and advancing drug development to offer hope to patients and their families.Explore more
Sapience Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Sapience Therapeutics
Compare insights from companies similar to Sapience Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Sapience Therapeutics Tech Stack
A closer look at the technologies used by Sapience Therapeutics
See more technologies
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Sapience Therapeutics
Sign Up For FreeTo access detailed company insights
Sapience Therapeutics is focused on revolutionizing oncology through innovative peptide therapeutics that target elusive oncogenic proteins. Their product pipeline includes SPEARs and SPARCs, with two lead candidates, lucicebtide (ST101) and ST316, currently in Phase 2 clinical trials. The company aims to provide precision therapies for patients wi... Read More
